Lenalidomid Amarox

Lenalidomide, the active ingredient in Lenalidomid Amarox, is an immunomodulatory drug presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic cancers, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomid Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company rigorously adheres to stringent quality standards and provides comprehensive regulatory documentation to support import and clinical use globally.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell or lymphoid proliferation. - Multiple myeloma: reduces disease progression and improves survival in adult patients. - Myelodysplastic syndromes: decreases transfusion dependence and delays transformation to acute leukemia. - Mantle cell lymphoma: induces tumor regression and prolongs remission in relapsed or refractory cases.

Lenalidomid Amarox may be associated with a range of adverse reactions, which are categorized by frequency. Common Side Effects: - Fatigue: persistent tiredness or lack of energy. - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of sickness or urge to vomit. - Rash: skin redness or irritation. - Constipation: difficulty passing stools or infrequent bowel movements. - Peripheral neuropathy: tingling, numbness, or pain in the hands or feet. Serious or Rare Side Effects: - Thromboembolic events: blood clots such as deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

When prescribing Lenalidomid Amarox, clinicians should observe several precautionary measures to minimize risk. - Pregnancy contraindication: drug is classified Category X and must not be used during pregnancy. - Contraception requirement: both male and female patients of reproductive potential must use effective contraception during treatment and for at least four weeks after discontinuation. - Thromboembolic risk: assess patient history of clotting disorders and consider prophylactic anticoagulation when appropriate. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia, anemia, or thrombocytopenia. - Renal/hepatic impairment: adjust therapy or monitor closely in patients with significant kidney or liver dysfunction. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Lenalidomid Amarox can interact with other medicines, influencing efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers: agents such as rifampin markedly reduce lenalidomide exposure and should be avoided. - Anticoagulants: concurrent use may increase risk of thrombotic or bleeding complications; careful monitoring is required. - Immunosuppressants: may diminish the immunomodulatory effect of lenalidomide. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: drugs like ketoconazole can increase lenalidomide levels, necessitating dose adjustment. - NSAIDs: may exacerbate gastrointestinal toxicity when combined. - Live vaccines: reduced efficacy and potential infection risk; avoid during therapy.